# A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

Source: https://onco.cc/trials/nct07604285/  
OnCo record `nct07604285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MT-125 run by Myosin Therapeutics Inc., not yet recruiting.

## Summary

A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma is a phase 1/2 interventional study registered as NCT07604285 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-07. Conditions recorded: Glioblastoma. Interventions recorded: MT-125.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07604285
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation and Randomized Expansion Study of Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
- Sponsor: Myosin Therapeutics Inc.
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07604285: https://clinicaltrials.gov/study/NCT07604285

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [MT-125](https://onco.cc/drugs/mt-125/)
- companies: [Myosin Therapeutics](https://onco.cc/companies/myosin-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07604285.json